Many studies have shown that elevated inflammatory markers, such as neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR), are associated with poor prognosis in patients with different solid malignancies. It is well recognized that systemic inflammation plays an important role in promoting tumor progression. Among them, while luminal A tumors have been reported to be the least likely to achieve pCR after neoadjuvant therapy, followed by luminal B tumors–which show a moderate response-, Her2-enriched and TN tumors exhibit the highest pCR rates. However, achieving a pCR after neoadjuvant therapy is associated with several pathologic and biologic factors such as histologic grade, hormone receptor status, and expression of Her2 and Ki67, among others. In the United States, the Food and Drug Administration (FDA) has recommended inclusion of pathologic complete response (pCR) as a main requirement for the accelerated approval of drugs used for neoadjuvant therapy in early-stage, high-risk breast cancer. Pathological complete response (pCR) to neoadjuvant chemotherapy in breast cancer patients is of prognostic value in determining short-, and mid-term outcomes, and is one of the main objectives in current ongoing studies assessing the potential benefit of neoadjuvant chemotherapy. Our results suggest that breast cancer patients with low platelet-to-lymphocyte ratio (PLR <150), treated with neoadjuvant chemotherapy achieve higher complete pathological response, independently of primary tumor molecular subtype. In addition, Her2-enriched tumors achieved the highest pCR rates (65%), followed by TN (34%) tumors. PLR was not associated with age, menopausal status, baseline tumor size, histologic grade, axillary lymph node involvement, disease stage, estrogen receptor status, or Ki67 however, complete pathological response was significantly higher in the low PLR group (PLR<150) compared with the high PLR group (35.1% Vs.

In our cohort, the most frequent tumor molecular subtype was luminal B/Her2- (27.8%) followed by triple negative (21.5%), luminal B/Her2+ (19.8%), Her2-enriched (16%) and luminal A (13.5%). Disease was locally advanced in 83% of the participants, and 77.7% had compromised lymph nodes. A total of 288 patients were included in the study, with a median age of 51 years old. Therefore, in this study we performed a cross-sectional study and analyzed the association between inflammatory biomarkers and pCR (pathological complete response) in patients diagnosed with breast cancer–of different molecular subtypes- and treated with neoadjuvant chemotherapy. Currently, there are no studies in Colombian patients reporting the role of inflammatory biomarkers as response predictors in patients receiving neoadjuvant chemotherapy. Inflammatory biomarkers, such as platelet-to-lymphocyte ratio (PLR) and neutrophil to lymphocyte ratio (NLR), have been proposed as predictive factors of response to neoadjuvant chemotherapy. Response to neoadjuvant chemotherapy in breast cancer patients is of prognostic value in determining short- and mid-term outcomes.

Crosstab midterm predictor